PharmaCyte Biotech
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on $333,763 over the previous period. Total operating expenses were $8,520,008.
Profit Margin
| 2015 | 0 | -10.85M | |
|---|---|---|---|
| 2016 | 0 | -6.06M | |
| 2017 | 0 | -4.44M | |
| 2018 | 0 | -6.82M | |
| 2019 | 0 | -4.06M | |
| 2020 | 0 | -3.82M | |
| 2021 | 0 | -3.55M | |
| 2022 | 0 | -4.08M | |
| 2023 | 0 | -4.31M | |
| 2024 | 0 | 333.76K |
PMCB Income Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating exp. | ||||||||||
Research and development | 407.43K | 468.53K | 690.93K | 916.24K | 301.22K | 460.05K | 1.99M | 1.18M | 1.40M | 3.47M |
Selling and marketing | 1.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 230.5K |
Total operating expenses | 8.52M | 6.45M | 4.39M | 3.62M | 3.82M | 4.10M | 6.98M | 4.44M | 6.07M | 13.69M |
Operating income | -6.52M | -6.45M | -4.39M | -3.62M | -3.82M | -4.10M | -6.98M | -4.44M | -6.07M | -13.69M |
Other income (expenses), net | 6.85M | 2.13M | 152.85K | 71.74K | -493 | 33.40K | 152.58K | -1.53K | 10.54K | 2.84M |
Income before tax | 333.76K | -4.31M | -4.23M | -3.55M | -3.82M | -4.06M | -6.82M | -4.44M | -6.06M | -10.85M |
Income tax expense | 0 | -1.93M | -153.36K | 3.04K | 453 | -33.40K | -152.58K | -4.44K | -4.88K | 4.93K |
Net income | 333.76K | -4.31M | -4.08M | -3.55M | -3.82M | -4.06M | -6.82M | -4.44M | -6.06M | -10.85M |
Earnings per share | ||||||||||
Basic EPS | -1.8 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.89 | -12.09 | -23.11 |
Diluted EPS | -1.8 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.88 | -12.08 | -23.11 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |